KraneShares CSI China Internet ETF vs Relay Therapeutics Inc. Common Stock — how do they compare? KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B), while Relay Therapeutics Inc. Common Stock trades at $17.88 (market cap $3.82B). The key difference: KraneShares CSI China Internet ETF and Relay Therapeutics Inc. Common Stock are close in size by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| KWEB | RLAY | |
|---|---|---|
Market Cap | $4.37B | $3.82B |
Volume | 13,393,361 | 4,332,079 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $20.75 |
52-Week Low | $23.63 | $6.03 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $2.93B |
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.93, up 2.47% today but maintains a bearish technical outlook with all 13 moving averages signaling sell. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent institutional activity shows mixed sentiment with Tidal Investments reducing its stake by 39.1% while HSBC increased its position by 27.7% in recent quarters.
The China internet ETF remains under pressure from geopolitical tensions and economic rebalancing concerns. While corporate profits surged 26% in Q2 2026, ongoing U.S.-China trade dynamics and potential export curbs create uncertainty. Technical indicators suggest continued bearish momentum with key support at $24.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →